Bausch Health (BHC)
(Delayed Data from NYSE)
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
BHC 9.38 +0.18(1.96%)
Will BHC be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BHC
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
Other News for BHC
Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Tracking Carl Icahn's 13F Report - Q4 2023 Update
Bausch Health Companies to Present at Cowen Annual Health Care Conference